The FDA granted breakthrough therapy designation to TERN-701 for adults with Philadelphia chromosome-positive CML without the ...

MSD's TROP2-targeting antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), licensed from China's Kelun-Biotech, has improved survival in a late-stage endometrial cancer trial. The positive ...

Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma (DLBCL), has demonstrated promise in a Phase II/III study, as the company ...

Ingenia wins KOSDAQ nod, advances MSD-partnered eye drug to global phase 3 Boston-founded biotech aims IPO as MSDs macular ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across over 25 types of cancer from the company’s comprehensive ...

(Nasdaq: EXEL) today announced that the company has entered into a clinical development collaboration with Merck, known as MSD outside of the United States and Canada, to supply KEYTRUDA QLEX™ ...

MSD India launched a cervical cancer awareness campaign with Madhuri Dixit Nene to encourage women and parents to discuss cervical cancer prevention and healthcare options with doctors.

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...